biomarker

2:13
The value of PD-L1 as a biomarker beyond lung cancers
Kevin Harrington
2:52
OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
Georgina Long
3:00
Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC
Thomas Powles
1:18
Vinorelbine in Mesothelioma: the upcoming VIM trial
Dean Fennell
2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna
3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
2:25
Molecular aging and p16INK4a in testicular cancer survivors
Maria Teresa Bourlon
1:24
How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?
Jacob Kettle
1:26
Assessment and diagnostic workup for NSCLC in 2018
Nathan Penell
2:11
Economic impact of NGS for NSCLC diagnostics
Nathan Penell
1:49
Using immunotherapy wisely for prostate cancer
Gerhardt Attard
1:37
Olaparib plus abiraterone for mCRPC: are biomarkers necessary?
Gerhardt Attard
3:34
ABACUS trial: preoperative atezolizumab in urothelial carcinoma
Thomas Powles
2:18
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
Thomas Powles
3:22
Drugs with low response rates – should they always be offered to patients?
Jacob Kettle
3:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Jacob Kettle
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals